PSN-632408

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H24N4O4
Molecular Weight	360.4076
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)OC(=O)N1CCC(CC1)OCC2=NC(=NO2)C3=CC=NC=C3

InChI

InChIKey=LHZWKWCEAXQUMX-UHFFFAOYSA-N

InChI=1S/C18H24N4O4/c1-18(2,3)25-17(23)22-10-6-14(7-11-22)24-12-15-20-16(21-26-15)13-4-8-19-9-5-13/h4-5,8-9,14H,6-7,10-12H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C18H24N4O4
Molecular Weight	360.4076
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16517404
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/21902730 | https://www.ncbi.nlm.nih.gov/pubmed/27413754

PSN632408 is an optimized agonist of GPR119 receptors. Systemic administration of PSN632408 suppresses food intake, reduces weight gain and white adipose tissue deposition in rats. PSN632408 treatment improved the function and/or mass of β-cells, significantly increased both human α- and β-cell areas in islet grafts and stimulated α- and β-cell replication. PSN632408 may be useful as a therapeutic agent for the treatment of obesity, diabetes and related metabolic disorders.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucose-dependent insulinotropic receptor 13 Target ID: CHEMBL5652 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16517404	Agonist 2678		5.6 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16517404	Primary		Preclinical	Unknown Approved Use Unknown
Diabetes mellitus 91 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27413754 https://www.ncbi.nlm.nih.gov/pubmed/21902730	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Activation of GPR119 Stimulates Human β-Cell Replication and Neogenesis in Humanized Mice with Functional Human Islets.	2016	27413754

Patents

Sample Use Guides

In Vivo Use Guide

100 mg/kg was administered daily for 14 days

Route of Administration: Oral

In Vitro Use Guide

The HEK-OSGPR116 cell line was used to investigate the effect of GPR119 agonists on intracellular levels of cyclic AMP (cAMP). Treatment with PSN632408 produced concentration-dependent increases in cAMP level with mean EC50 values of 1.9 uM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:09:28 GMT 2023` Edited by `admin` on `Sat Dec 16 09:09:28 GMT 2023`
Record UNII	V4434XWK2P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PSN-632408

Code

English

1-PIPERIDINECARBOXYLIC ACID, 4-((3-(4-PYRIDINYL)-1,2,4-OXADIAZOL-5-YL)METHOXY)-, 1,1-DIMETHYLETHYL ESTER

Systematic Name

English

1,1-DIMETHYLETHYL 4-((3-(4-PYRIDINYL)-1,2,4-OXADIAZOL-5-YL)METHOXY)-1-PIPERIDINECARBOXYLATE

Systematic Name

English

TERT-BUTYL 4-((3-(PYRIDIN-4-YL)-1,2,4-OXADIAZOL-5-YL)METHOXY)PIPERIDINE-1-CARBOXYLATE

Systematic Name

English

PSN632408

Code

English

Code System Code Type Description

EPA CompTox

DTXSID80466726